Centessa Pharmaceuticals plc (CNTA)
Jun 24, 2026 - CNTA was delisted (reason: acquired by LLY)
40.50
+0.32 (0.80%)
Inactive · Last trade price on Jun 23, 2026

Centessa Pharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
6,2673,7322,2227662941,013
Market Cap Growth
293.44%68.00%190.19%160.39%-70.98%-
Enterprise Value
6,1083,5551,857593.61-29.831,013
Last Close Price
40.5025.0116.757.963.1011.26

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
-248.81-111.71--
PB Ratio
12.867.085.533.240.87-
P/TBV Ratio
11.706.444.783.240.86-

EV Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EV/Sales Ratio
-237.02-86.62--
EV/EBITDA Ratio
----0.14-
EV/EBIT Ratio
----0.14-
EV/FCF Ratio
----0.15-

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
0.240.220.290.360.21-
Net Debt / Equity Ratio
-0.33-0.34-0.91-0.73-0.96-
Net Debt / EBITDA Ratio
0.620.861.821.011.53-
Net Debt / FCF Ratio
0.760.912.571.071.61-
Asset Turnover
-0.0200.0200
Quick Ratio
9.118.129.077.4710.90-
Current Ratio
9.538.579.258.0011.42-
Return on Equity (ROE)
-49.43%-42.55%-73.93%-52.79%-128.63%0.00%
Return on Assets (ROA)
-38.82%-33.16%-43.44%-36.52%-95.22%0.00%
Return on Invested Capital (ROIC)
-76.04%-107.40%-388.75%-383.41%-3432.57%0.00%
Return on Capital Employed (ROCE)
-41.08%-35.71%-47.89%-47.13%-104.57%0.00%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Buyback Yield / Dilution
-14.73%-18.56%-19.02%-2.97%-3.79%-2196.70%
Total Shareholder Return
-14.73%-18.56%-19.02%-2.97%-3.79%-2196.70%
SEC Filings: 10-K · 10-Q